Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Cimetidine on Lucerastat PK in Healthy Males
NCT03380455Phase 1Completed
- Sponsor
- Idorsia
- Start
- Jan 2018
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lucerastat in Fabry disease (FD), sponsored by Idorsia. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 4 more. Started Jan 2018; status: completed.
02
Drugs
lucerastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT03380455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03380455.